⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1186779 | 0.98 | — | — | |
| Benzene SCHEMBL28044738 | 0.96 | CYP2C9 (0.53) | — | |
| SCHEMBL9597765 | 0.82 | — | — | |
| SCHEMBL6132965 | 0.79 | CYP2C9 (0.60) | — | |
| SCHEMBL419467 | 0.78 | — | — | |
| SCHEMBL246132 | 0.76 | — | — | |
| SCHEMBL18411683 | 0.76 | — | — | |
| SCHEMBL906384 | 0.76 | — | — | |
| SCHEMBL9602988 | 0.76 | — | — | |
| SCHEMBL18192 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | claimed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | claimed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | claimed |
| WO-2026103873-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 杭州百新生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-3746436-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | DRAIG THERAPEUTICS LTD. (GB) | 2025-06-19 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-1046286-C | Novel cephem derivatives | MEIJI SEIKA CO (JP) | 1999-11-10 | — | — | CN | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| US-5870275-A | CONTAINING A QUATERNARY AMIDINE GROUP | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1999-02-09 | — | — | US | disclosed |
| WO-1998050385-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
| CN-1114507-A | Novel cephem derivatives | MEIJI SEIKA CO (JP) | 1996-01-03 | — | — | CN | disclosed |
| EP-0684620-A1 | ELECTROLYTIC SOLUTION AND ELECTROCHEMICAL ELEMENT PREPARED THEREFROM | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
| WO-1993023402-A1 | 3-AZETIDINYLTHIO-CARBAPENEME DERIVATIVES, THEIR PREPARATION AND USE AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-25 | — | — | WO | disclosed |
| US-4505918-A | HYPOTENSIVE AND ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1985-03-19 | — | — | US | disclosed |